Objectives: Aim of the present study was to assess the prevalence of right (RV) or left ventricle (LV) systolic and/or diastolic dysfunction by standard echocardiography and tissue Doppler imaging (TDI).

Methods: Thirty patients with UCTD-risk-SSc (28 female, aged 47±13 years, range 21–70) and 30 age- and sex-matched controls underwent cardiac assessment by standard echocardiography and TDI.

Results: UCTD-risk-SSc patients and controls did not show any difference at standard echocardiographic evaluation. In particular, an inverted E/A ratio was pointed out in 10/30 patients and 7/30 controls (p=ns). TDI showed a mild impairment of LV and RV diastolic (E_m 15±4 vs 19±5, $p<0.0001$; E/E_m 6.1±1.7 vs 4.8±1.2, $p=0.001$; E_r 14±3 vs 16±2, $p=0.02$; E_r/A_r 0.9±0.4 vs 1.3±0.3, $p<0.002$; increased pulmonary artery wedge pressure 9±2 vs 8±1, $p=0.001$) and systolic function (S_m 13±3 vs 15±2 cm/sec, $p<0.0003$; S_r 14±2 vs 16±3 cm/sec, $p<0.0001$) in UCTD-risk-SSc patients in comparison to controls.

Conclusions: Our study shows that UCTD-risk-SSc patients present a previously unrecognized, mild biventricular systolic and diastolic dysfunction as compared to controls. The pathophysiologic meaning (i.e. intramyocardial artery disease and/or patchy fibrosis) as well the predictive value of developing overt SSc in the short time await to be elucidated.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.3080

FRI0379 PREVALENCE OF FAM111B GENE MUTATIONS IN SYSTEMIC SCLEROSIS

A. Gcelu¹, G. Deshpande², A.A. Kalla¹, M. Tikly³, B. Mayosi², B. Hodgkinson¹.
¹Medicine, Division of Rheumatology; ²Cardiovascular Genetics Laboratory, University of Cape town, Cape Town; ³Medicine, Division of Rheumatology, University of Witwatersrand, Johannesburg, South Africa

Background: Systemic sclerosis (SSc) is a prototypic systemic fibrotic disease with unclearly characterized genetic basis. Implicated genes have been associated with autoimmune dysregulation with relatively few variants associated with fibrosis [1]. We have discovered that mutations in *FAM111B* gene cause hereditary fibrosing poikiloderma with tendon contractures, myopathy, and pulmonary fibrosis (POIKTMP)[2], a multisystem fibrotic condition with clinical aspects of SSc [3]. This observation has established *FAM111B* as a candidate gene for SSc.

Objectives:

The objective is to investigate whether *FAM111B* gene mutations are present in SSc patients and further explore relationships between *FAM111B* mutations and clinical expression of SSc.

Methods: Patients with a definite diagnosis of SSc attending the Rheumatology outpatient departments at Groote Schuur Hospital, Cape Town, and Chris Hani Baragwanath Hospital, Johannesburg, were enrolled into the study. Physical examination assessing the extent of disease was done in all patients and the modified Rodnan skin score (mRSS) was used to determine the extent of the skin involvement. Blood samples were collected for DNA extraction and mutation screening using the high-resolution melt technique. Samples with abnormal electropherograms were selected for Sanger sequencing to identify mutations. Public databases were used to verify the frequency of variants in *FAM111B*.

Results: 131 patients were genotyped, 13 men and 118 women, with a mean age of 26.6 years and mean age of symptom onset at 25.3 years. The majority of patients were black (59.5%). 72% of patients had diffuse systemic sclerosis (DSSc) with a median mRSS of 11. Genetic analysis revealed seven rare genetic variants (C832G>A; C855G>T; C917A>G; C937G>A; C988C>T; C995A>C and C1006G>C) in eight patients (five patients from Johannesburg and three patients from Cape Town) [Table 1]. These variants were missense mutations of unknown significance with a minor allele frequency <0.01. No *FAM111B* mutations that cause POIKTMP were found in patients with SSc.

Conclusions: Rare genetic variants of unknown significance (GVUS) in *FAM111B* gene were found in patients with SSc. It is possible that the GVUS may modify the function of *FAM111B*, and influence the pathogenesis of SSc or are rare polymorphisms with no functional impact.

References:

- [1] Romano, E., et al., The genetics of systemic sclerosis: an update. *Clin Exp Rheumatol*, 2011. 29(2 Suppl 65): p. S75–86.
- [2] Mercier, S., et al., Mutations in *FAM111B* cause hereditary fibrosing poikiloderma with tendon contracture, myopathy, and pulmonary fibrosis. *Am J Hum Genet*, 2013. 93(6): p. 1100–7.
- [3] Khumalo, N.P., et al., Poikiloderma, tendon contracture and pulmonary fibrosis: a new autosomal dominant syndrome? *Br J Dermatol*, 2006. 155(5): p. 1057–61.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.6719

FRI0380 PATIENT PREFERENCES AND DIFFICULTIES CONCERNING THE HOME TREATMENT OPTIONS IN SYSTEMIC SCLEROSIS (SSc)

B. Pagnotelli¹, C. Bruni¹, S. Bellando Randone¹, S. Guiducci¹, G. Lepri¹, J. Blagojevic¹, L. Rasero², M. Maticucci Cerinic¹, D.E. Furst^{1,3}. ¹Division of Rheumatology; ²Division of Research & Development Clinical Practice,

AOUC, Florence, Italy; ³Division of Rheumatology, UCLA, Los Angeles, United States

Background: SSc patients suffer from Raynaud's phenomenon, hand skin hardening and scarring, digital ulcers, esophagus/gastric dysmotility, dysphagia and mucosal dryness. These symptoms significantly reduce patient's life autonomy and impair the capacity to handle their therapy usually made by different modalities of administration: oral, topical, inhalation, intramuscular, subcutaneous, intravenous, and rectal.

Objectives: to investigate the methods of administration used by SSc patients, their preferred methods, their compliance to pharmacological therapy, and the difficulties that are encountered by the patients during pharmacotherapy.

Methods: 2 questionnaires were prepared on an ad hoc basis. The first given to patients, the second to be filled out by the patient's physician. The first questionnaire comprised 25 questions to investigate the problems encountered by patients when taking their medications by correlating these with two validated activities indices: SHAQ-DI (activities of daily living) and the COCHIN scale (hand activities). The second questionnaire collected demographic and important SSc-related clinical information (eg. age, sex, disease duration, symptoms). 80 SSc patients completed the questionnaires, maintaining anonymity. A "difficulty index" was also filled out, where: 0 = no difficulty to 4 = impossible to use or too difficult to use.

Results:

Table 1. Patient use of pharmacological therapies

	% Using	% Users preferring this method	Difficult index [†]	Comment
Oral	100	91,25	0,83	Most preferred
Eye drops	52,5	2,5	1,07	Least preferred
Topicals	33,75	3,75	0,77	Cannot open the top (safety lock)
Injections	28,25	2,5	2,17	Cannot apply to skin
Inhaler	16,25	0	1,07	Cannot spray
Vaginal/rectal	6,25	0	1,03	

Table 2. Most frequent problems encountered

	% Using	Most frequent problems	Users have these problems	Difficult index [†]
Oral	100	Blister: pushing out pills	73,75	2,22
Eye drops	52,5	Open thin stoppers	78,75	1,51
Topicals	33,75	Cannot open the top (safety lock)	70,5	1,4
Inhaler	16,25	Cannot spray/push the inhaler	85	1,71

[†]4 = most difficult.

In particular, the dimension of the pills is problematic, and has identified a paradoxical situation because large pills are difficult to swallow (41,25% patients who use pills) but at the same time small pills are difficult to pinch with the fingers (62,25% patients who use pills).

Conclusions: SSc patients experience significant problems in maintaining adherence to treatments due to difficulties in the use of blisters and bottles with children proof stoppers. Pills still remain the most preferred method of treatment. In conclusion, patients unanimously wished to avoid the use of blisters, definitely preferring bottles without the children proof stopper to make the treatment easier and provide a more independent life.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.4848

FRI0381 INCREASED RISK OF OSTEOPOROTIC FRACTURES IN ADULT PATIENTS WITH POLYMYOSITIS AND DERMATOMYOSITIS: A NATIONWIDE POPULATION-BASED COHORT STUDY

C.-C. Lai¹, W.-S. Chen¹, Y.-P. Tsao¹, Y.-S. Chang². ¹Division of Allergy, Immunology, and Rheumatology, Taipei Veterans General Hospital, Taipei City; ²Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan, Province of China

Background: Patients with polymyositis and dermatomyositis (PM/DM) are characterized by chronic muscle weakness due to autoimmune-mediated myositis and are usually treated with corticosteroids initially. PM/DM patients prone to develop osteoporosis and subsequent fractures but are rarely investigated.

Objectives: To explore the incidence rate (IR) and risk factors of osteoporotic fractures (OFs) among adult PM/DM patients.

Methods: We conducted a cohort study by utilizing the Taiwan National Health Insurance database. PM/DM patients and respective age- and gender-matched cohort without PM/DM were enrolled. The primary endpoint was the initial event of OFs. We used the Cox proportional hazard model to study the risk factors of OFs in the PM/DM cohort.

Results: Among 2391 PM/DM patients (67.8% female, mean age: 49.5 years) followed for a mean (SD) of 6.1 (5.0) years, 116 developed vertebral fractures, 32 had hip fractures, and 14 experienced radius fractures (IR: 8.18, 2.20, and 0.96 per 1000 person-years, respectively, Table 1). Compared with the matched cohort, the PM/DM patients had higher IR ratios (IRRs) (95% CIs) of OFs at all age groups at enrollment: 3.27 (2.19 to 4.81, $p<0.0001$) for people <50 years and 2.29 (1.85 to 2.82, $p<0.0001$) for those ≥50 years. The IRRs were 2.39 (1.92

to 2.94, $p < 0.0001$) for vertebral fractures and 1.62 (1.07 to 2.38, $p = 0.0093$) for hip fractures. PM/DM patients experienced vertebral fractures and hip fractures at younger ages (62.2 vs 68.4 and 66.0 vs 75.4 years, respectively; both $p < 0.001$). Multivariable Cox regression analyses showed that being female gender, age ≥ 50 years, having hypertension, coronary artery disease, asthma, and using daily prednisolone equivalent to > 5 mg are associated with OFs.

Table 1. IRs and IRRs of osteoporotic fractures: overall and subgroup analysis

Subgroup	IM IR	Control IR	IRR (95% CI)	p Value
Overall fracture	10.90	5.23	2.08 (1.73 to 2.49)	<0.0001
Age <50 year	4.51	1.38	3.27 (2.19 to 4.81)	<0.0001
Age ≥ 50 year	22.59	9.85	2.29 (1.85 to 2.82)	<0.0001
Vertebral fracture	8.18	3.43	2.39 (1.92 to 2.94)	<0.0001
Age <50 year	3.39	0.98	3.47 (2.17 to 5.44)	<0.0001
Age ≥ 50 year	16.82	6.33	2.66 (2.07 to 3.39)	<0.0001
Hip fracture	2.20	1.36	1.62 (1.07 to 2.38)	0.0093
Age <50 year	0.65	0.10	6.56 (1.75 to 24.6)	0.0027
Age ≥ 50 year	4.87	2.83	1.72 (1.09 to 2.62)	0.0081
Radius fracture	0.96	0.83	1.15 (0.60 to 2.02)	0.3081
Age <50 year	0.43	0.35	1.25 (0.31 to 3.69)	0.3289
Age ≥ 50 year	1.86	1.40	1.35 (0.62 to 2.63)	0.1857

IR, incidence rate per 1000 person-year; IRR, incidence rate ratio; CI, confidence interval.

Conclusions: Adult PM/DM patients had a high IR of vertebral and hip fractures. Patients who were female, advanced age, having certain comorbidities, and exposed to corticosteroid exhibited a higher risk.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.6043

FRI0382 USE OF THE DETECT ALGORITHM FOR EARLY PULMONARY ARTERY HYPERTENSION DIAGNOSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS IN EVERYDAY CLINICAL PRACTICE

C. Koutsianas, S. Subasinghe, K. Douglas. *Department of Rheumatology, The Dudley Group NHS Foundation Trust, Dudley, United Kingdom*

Background: The DETECT algorithm (DA)¹ provides a sensitive tool for early identification of patients with Systemic Sclerosis (SSc) at risk of Pulmonary Arterial Hypertension (PAH) and advocates evaluation with Right Heart Catheterisation (RHC). Few published data look into its implementation in everyday clinical practice and compare it to annual echocardiographic (TTE) screening.

Objectives: To compare DA and TTE screening of SSc patients for RHC referral rates and related patient characteristics.

Methods: Data on 57 consecutive patients with a diagnosis of SSc that had at least one visit to Russell's Hall Hospital Scleroderma clinic from February to November 2016 was prospectively collected on Excel (clinical history, physical examination, immunological status, treatment, PFTs, NT-proBNP, urate, ECG, TTE, CXR and HRCT results). DETECT scores were calculated (www.detect-pah.com) and compared with the TTE probability for PAH as per the 2015 ESC/ERS Guidelines².

Results: 31 patients with a full set of data were included in the final analysis. 93.5% were female with a mean age of 64.4 $\pm$ 12.9 years, 87% had limited cutaneous (lc) SSc, 58.1% positive antitopoisomerase antibody and mean time since diagnosis was 6.2 $\pm$ 3.2 years. The majority of patients (80%) were asymptomatic

for PAH. Mean DLCO was 60.9 $\pm$ 18.3% predicted (the DETECT study included on patients with DLCO $< 60\%$). We did not exclude patients with renal insufficiency; mean eGFR was 74 $\pm$ 17.7 ml/min.

The implementation of DA recommended RHC in 18/31 patients (DETECT step 2 score ≥ 35 , 58%, see table 1) compared to just 4/31 (13%) based on TTE by 2015 ESC/ERS guidelines. The additional 14 patients identified by DA were found to have no statistically significant differences in SSc type, dyspnea symptomatology, immunosuppressive treatment, presence of interstitial lung disease (ILD), age, time from diagnosis or symptom onset, eGFR and CRP compared to patients where RHC was not recommended. From the 18 patients identified by DA, only 4 reported shortness of breath. 2/18 had existing cardiac conditions (aortic stenosis, left ventricular hypertrophy), while 9/18 had ILD (5 mild, 2 moderate, 2 severe as per HRCT).

Table 1

	DETECT step 2 score			p
	<35	35-39	>40	
Age, years (median (IQR))	65.8 (26.9)	63.2 (22.3)	72.4 (25.1)	0.875
Disease duration, years (median (IQR))	8 (4)	4 (7)	5 (9)	0.996
eGFR, ml/min (median (IQR))	80 (28)	83 (17)	54.5 (47)	0.958
CRP, mg/L (median (IQR))	3 (5)	3 (3)	3 (2)	0.636
DLCO, % (median (IQR))	65 (17)	64 (12)	53 (30)	0.757
ILD (no. of patients)	No			
Mild	10	5	3	0.087
Moderate	1	3	4	
Severe	2	1	0	
	0	0	2	

Conclusions: Implementation of DA in a largely asymptomatic non-selected SSc patient population is more sensitive for RHC referral than annual TTE screening. Recommendations for RHC per DETECT score are difficult to predict on symptom and other traditional clinical parameters. The use of DA will lead to increased RHC referrals. Cardiologists may need education on this new method for screening and although the ESC/ERS 2015 guidelines discuss DA, they conclude that its cost-effectiveness has not been clarified as compared with symptom-based detection.

References:

- [1] Coghlan JG et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. *Ann Rheum Dis* 2014 Jul;73 (7):1340-9.
- [2] Galiè N et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Heart J* (2015) 37 (1): 67-119.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.5928

FRI0383 DETECT SCREENING FOR PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC SCLEROSIS: DATA FROM AN EUSTAR COHORT

C. Ancuta^{1,2}, C. Pomirleanu^{1,2}, R. Maxim², F. Mitu^{1,3}. ¹University of Medicine and Pharmacy Grigore T Popa Iasi; ²Rheumatology 2; ³Cardiology, Clinical Rehabilitation Hospital, IASI, Romania

Background: Early documentation of pulmonary arterial hypertension (PAH) related to systemic sclerosis (SSc) remains a challenge in daily clinical practice, with major prognostic and therapeutic implications. Although several screening algorithms specifically designed to optimize the detection of secondary PAH have already been proposed (e.g., DETECT, REVEAL), no precise approach received complete validation, especially the use of invasive diagnostic right heart catheterization (RHC).

Objectives: Main objective was to assess the risk of PAH in patients with SSc and to compare with PAH screening promoted by European Society of Cardiology/ European Respiratory Society (ESC/ERS) 2009 guidelines, while secondary one to identify predicting factors for developing PAH among clinical and immunological SSc variables.

Methods: Cross-sectional prospective single-center study, applying the DETECT calculator in patients with SSc recruited in EUSTAR 162 center cohort between January 2013- December 2016; all SSc completing at least two monitoring visits at 6 months were considered.

Standard assessments included MEDS (minimal data set EUSTAR), annual echocardiography with systolic pulmonary artery pressure (sPAP), pulmonary function tests with forced vital capacity (FVC), percentage predicted/diffusing capacity for carbon monoxide (DLCO) % predicted, ECG, serum biomarkers (serum urate, NT-proBNP).

PAH risk calculator (<http://detect-pah.com/pah-risk-calculator>), a tool developed and validated in the DETECT study, is able to identify patients requiring echocardiography (STEP 1) respectively RHC (STEP 2), and was systematically applied in our cohort. All sPAP ≥ 45 mmHg or between 35-45 mmHg in the presence of dyspnea were proposed for invasive testing.

Statistical analysis was performed in IBM SPSS-19 version, $p < 0.05$.

Results: 41 out of 56 SSc in our database were recruited: mainly women (85.36%) with diffuse cutaneous SSc (63.41%), anti-topoisomerase (up to half) and anti-centromere (about one third) positive disease; one out of four SSc presented with digital ulcers and one of three with active capillaroscopic pattern.